France · Delayed Price · Currency is EUR Inventiva Earnings Call Transcripts
Fiscal Year 2026
-
Lanifibranor's Phase III trial for MASH is well-powered and builds on strong Phase IIb results, targeting F2/F3 patients with a favorable safety profile and differentiated market positioning. The company plans independent commercialization, with a cash runway through Q3 2027.
-
Lanifibranor's phase 3 program for MASH is on track for pivotal data in late 2024, with a focus on F2/F3 patients and a robust safety profile. Regulatory and commercial strategies are well-defined, with plans for accelerated approval, an F4 outcomes study, and patent protection through 2041.
-
NATiV3 phase III trial aims for a strong dual endpoint in F2/F3 NASH, with conservative powering and a focus on safety and tolerability. Commercial strategy targets both diabetic and non-diabetic populations, with future plans for F4/cACLD outcome studies and combination therapies.
-
Lanifibranor's phase III trial in MASH is fully enrolled, with top-line data expected in the second half of the year. The company is well-capitalized, targeting a large and growing market, and is positioned for both independent launch and strategic partnerships, with a focus on diabetic F2/F3 patients.
-
Significant transformation and funding have positioned the company to advance lanifibranor, a pan-PPAR agonist for MASH, through a fully enrolled phase III trial with data expected later this year. Strategic preparations for commercialization and a robust cash runway support a potential 2028 launch.
Fiscal Year 2025
-
Inventiva completed NATiV3 phase III enrollment for lanifibranor in MASH, expects top-line data in Q4 2026, and is well-funded through key milestones. Strategic focus, leadership expansion, and divestment of odiparcil position the company for regulatory and commercial readiness.
-
A strengthened balance sheet and experienced leadership position the company for a pivotal 2026, with the Phase III NATiV3 trial for lanifibranor in MASH set to read out in the second half of next year. The study's robust design, market positioning, and operational readiness support a strong commercial launch strategy.
-
Lanifibranor is positioned for a 2028 launch as a best-in-class oral therapy for MASH, supported by strong phase II-B data and a fully enrolled phase III trial. The company is preparing for a rapidly evolving market, emphasizing combination therapies, holistic patient care, and broad metabolic benefits.
-
Lanifibranor, a pan-PPAR in phase III for NASH, is positioned as a differentiated therapy with strong antifibrotic and insulin-sensitizing effects, targeting both fibrosis and type-2 diabetes. Global partnerships, robust funding, and upcoming pivotal data in 2026 support its market potential.
-
Lanifibranor shows strong efficacy and safety in advanced fibrosis and type 2 diabetes, with Phase III enrollment nearly complete and interim data mirroring Phase IIb results. Robust financial backing and strategic positioning support plans for NDA filing in 2027 and potential approval in 2028.
Fiscal Year 2024
-
Significant clinical and financial progress was made, with Lanifibranor advancing in phase III and a strengthened cash position from major financings. Strategic focus is now solely on Lanifibranor, with international development funded by partners and a clear path to NDA filing in 2027.